Kits19 segmentation challenge

In this work we briefly describe our methodology for the kidney segmentation problem

Contour-aware multi-label chest X-ray organ segmentation

© 2020, CARS. Purpose: Segmentation of organs from chest X-ray images is an essential task for an accurate and reliable diagnosis of lung diseases and chest organ morphometry. In this study, we investigated the benefits of augmenting state-of-the-art deep convolutional neural networks (CNNs) for image segmentation with organ contour information and evaluated the performance of such augmentation on segmentation of lung fields, heart, and clavicles from chest X-ray images. Methods: Three state-of-the-art CNNs were augmented, namely the UNet and LinkNet architecture with the ResNeXt feature extraction backbone, and the Tiramisu architecture with the DenseNet. All CNN architectures were trained on ground-truth segmentation masks and additionally on the corresponding contours. The contribution of such contour-based augmentation was evaluated against the contour-free architectures, and 20 existing algorithms for lung field segmentation. Results: The proposed contour-aware segmentation improved the segmentation performance, and when compared against existing algorithms on the same publicly available database of 247 chest X-ray images, the UNet architecture with the ResNeXt50 encoder combined with the contour-aware approach resulted in the best overall segmentation performance, achieving a Jaccard overlap coefficient of 0.971, 0.933, and 0.903 for the lung fields, heart, and clavicles, respectively. Conclusion: In this study, we proposed to augment CNN architectures for CXR segmentation with organ contour information and were able to significantly improve segmentation accuracy and outperform all existing solution using a public chest X-ray database

Refocusing of Attention on Positive Events Using Monitoring-Based Feedback and Microinterventions for Patients With Chronic Musculoskeletal Pain in the PerPAIN Randomized Controlled Trial: Protocol for a Microrandomized Trial

BackgroundChronic musculoskeletal pain (CMSP) affects between 13% and 47% of the population, with a global growth rate of 20.3% within the last 15 years, suggesting that there is a high need for effective treatments. Pain diaries have long been a common tool in nonpharmacological pain treatment for monitoring and providing feedback on patients’ symptoms in daily life. More recently, positive refocusing techniques have come to be used, promoting pain-free episodes and positive outcomes rather than focusing on managing the pain. ObjectiveThis study aims to evaluate the feasibility (ie, acceptability, intervention adherence, and fidelity) and initial signals of efficacy of the PerPAIN app, an ecological momentary intervention for patients with CMSP. The app comprises digitalized monitoring using the experience sampling method (ESM) and feedback. In addition, the patients receive 3 microinterventions targeted at refocusing of attention on positive events. MethodsIn a microrandomized trial, we will recruit 35 patients with CMSP who will be offered the app for 12 weeks. Participants will be prompted to fill out 4 ESM monitoring questionnaires a day assessing information on their current context and the proximal outcome variables: absence of pain, positive mood, and subjective activity. Participants will be randomized daily and weekly to receive no feedback, verbal feedback, or visual feedback on proximal outcomes assessed by the ESM. In addition, the app will encourage participants to complete 3 microinterventions based on positive psychology and cognitive behavioral therapy techniques. These microinterventions are prompts to report joyful moments and everyday successes or to plan pleasant activities. After familiarizing themselves with each microintervention individually, participants will be randomized daily to receive 1 of the 3 exercises or none. We will assess whether the 2 feedback types and the 3 microinterventions increase proximal outcomes at the following time point. The microrandomized trial is part of the PerPAIN randomized controlled trial (German Clinical Trials Register DRKS00022792) investigating a personalized treatment approach to enhance treatment outcomes in CMSP. ResultsApproval was granted by the Ethics Committee II of the University of Heidelberg on August 4, 2020. Recruitment for the microrandomized trial began in May 2021 and is ongoing at the time of submission. By October 10, 2022, a total of 24 participants had been enrolled in the microrandomized trial. ConclusionsThis trial will provide evidence on the feasibility of the PerPAIN app and the initial signals of efficacy of the different intervention components. In the next step, the intervention would need to be further refined and investigated in a definitive trial. This ecological momentary intervention presents a potential method for offering low-level accessible treatment to a wide range of people, which could have substantial implications for public health by reducing disease burden of chronic pain in the population. International Registered Report Identifier (IRRID)DERR1-10.2196/4337